Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.92), $0.36 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $4.66 million versus the consensus estimate of $786.1 thousand.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.